Dealmaking in the life sciences sector comes with characteristics not typically seen in more traditional mergers and acquisitions (M&A). Deals often involve negotiating around complexities associated with both the unique nature of assets of life sciences companies and the unique industry ecosystem that brings these assets to life. Buyers also come with different views, perhaps wanting to license a product, do a collaboration, or undertake an M&A. Given these traits, life sciences deals can be more creatively structured, sometimes featuring a combination of an M&A transaction, coupled with a partnership or co-commercialization agreement, spin offs, or options to buy.
Read the full article: Trends and Tips for Navigating Life Sciences M&A in 2024 //
Source: https://www.lexology.com/library/detail.aspx?g=7650f8c4-31f5-4351-b745-7a13cc03c364